InvestorsHub Logo
Followers 9
Posts 631
Boards Moderated 0
Alias Born 07/22/2013

Re: None

Friday, 10/03/2014 10:39:09 AM

Friday, October 03, 2014 10:39:09 AM

Post# of 43722
Well our total enrollees for the month of Sep (16) doesn't seem too bad, but I would have liked to see at least half again as many.

CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial

VIENNA, Va., Oct 03, 2014 (BUSINESS WIRE) -- CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of September the Company enrolled 16 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection).
"During this fall we expect to add about 15 new hospitals to our study. As active patient enrollment starts up in these centers we should see many more patients being enrolled every month," stated CEL-SCI Chief Executive Officer Geert Kersten.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVM News